

18 September 2023

ASX Announcement

## Notice of Annual General Meeting and Closing Date for Director Nominations

---

**Firebrick Pharma Limited** (ASX: FRE) (**Company** or **Firebrick**) advises that the Company's Annual General Meeting (**AGM**) is scheduled to be convened at 3.00pm (AEDT) on Friday, 17 November 2023.

The AGM will be held as a virtual meeting through an online meeting platform powered by Automatic, where Shareholders will be able to watch, listen, and vote online.

In accordance with the Company's Constitution, the closing date for receipt of director nominations to the Company from persons wishing to be considered for election as a director, is Friday, 29 September 2023. Any nominations must be received in writing at the Company's registered office by 5.00pm (AEST).

The AGM materials will be produced and provided to shareholders in due course.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

### About Firebrick Pharma

Firebrick is a pharmaceutical company founded in 2012 with the mission to develop and commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company owns numerous patents and other intellectual property around the use of intranasal povidone-iodine.

#### Media enquiries:

Heidi Cuthbert  
+61 411 272 366  
[heidi.cuthbert@multiplier.com.au](mailto:heidi.cuthbert@multiplier.com.au)

#### Investor enquiries:

[Investors@firebrickpharma.com](mailto:Investors@firebrickpharma.com)